Gilead Sciences Inc, an American biotechnology company that discovers, develops and commercializes therapeutics, said that its Chief Executive John Martin's total compensation package mounted 23% to about $19 million in 2014.

Because of its blockbuster hepatitis-C drug Sovaldi, revenue of the company was more than doubled in 2014, said the company. In 2013, total stock and option award of Mr. Martin was $13.6 million, up from $10.3 million.

According to the company, the board decided to increase his salary 2.4% to $1.6 million and was also given a bonus of $3.7 million, up 5% from 2013. Last year, sale of Gilead increased to $7.31 billion from $3.12 billion and its earnings mounted $3.46 billion from $ 787 million.

The progress was largely because of Sovaldi, a hepatitis C drug. At the end of 2013, this drug received approval by the Federal Drug Administration and has a cure rate exceeding 90%. Over the past decade, the company has raised its revenue more than 11-fold, and its free cash flow increased from just $667 million in 2005 to $12.3 billion in 2014.

“We are pleased to report that Gilead had strong financial performance across all of our therapeutic areas”, the company said in a filing with Securities and Exchange Commission.

Gilead’s hepatitis C treatment Sovaldi can cost patients up to $84,000 for a 12-week treatment. Martin's 2014 pay involved a $1.6 million salary, stock options worth $5.2 million, stock award valued at $8.4 million and $3.7 million incentive award. Since 1996, Martin is CEO and has scored eye-popping equity gains before. Total shareholder return of Gilead was 26% last year, following a 105% return in 2013.